ORPOF News and Press, OSE Immunotherapeutics SA From 04/16/24

OSE Immunotherapeutics’ Global License to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation Becomes Effective NANTES, France, April 16, 2024 – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage immunotherapy company, to...

OSE Immunotherapeutics Announces Peer-Reviewed Publication on Novel Myeloid Immune Checkpoint CLEC-1 in Journal of Immunology Nantes, France – April 2, 2024 – 7:30 am CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) to...

Financial highlights €18.7 million available cash as of December 31 st , 2023, not including the upcoming $48 million payment as part of the recent collaboration and license partnership (February 2024) with AbbVie 1 , nor the €5.8 million of R&D Tax credit, p...

Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) updates on its clinical portfolio advancements and provides 2024 outlook. Nicolas Poirier, Chief Executive Officer of OSE Immunotherapeutics, comments: “The Company has a broad portfolio of 5 products...

Novel antagonist anti-SIRPα monoclonal antibody (mAb) targeting both V1 and V2 SIRPα alleles makes SIRPα antagonists an option for more cancer patients. First clinical results of BI 770371 in monotherapy and in combination presented at ESMO 2023 conference. ...

Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) presented the first Phase 1/2 positive clinical results with high affinity anti-PD1 monoclonal antibody OSE-279 in advanced solid tumors at the AACR-NCI-EORTC International Conference on Molecular Targets and Ca...

Financial highlights Financial visibility secured over the next 12 months, until Q4 2024, supported by additive financing secured in H1-2023 and reduction of operating expenses. €15 million available cash as of June 30, 2023, supplemented by R&D tax credit of Ȋ...

Leading medical journal highlights peer-reviewed, randomized phase 3 clinical results with Tedopi® off-the-shelf T-cell epitope-based cancer vaccine monotherapy compared to chemotherapy in advanced non-small cell lung cancer (NSCLC) patients in secondary resistance to immune checkpoi...

Positive Review from the Drug Safety Monitoring Board (DSMB) on the Ongoing Phase 2 Clinical Trial in Ulcerative Colitis. Positive Opinion for Orphan Drug Designation from the European Medicines Agency in the Treatment of Acute Lymphoblastic Leukemia. Regulatory News: OS...

Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that the United States Patent and Trademark Office has granted a new patent protecting Tedopi®, a therapeutic cancer vaccine treating HLA-A2 positive patients after secondary resistance to PD-...